E3 Ubiquitin Ligase UBR5 Aggravates Cardiac Hypertrophy Via Inhibiting Nrf2/HO-1 Pathway.

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Drugs and Therapy Pub Date : 2026-10-01 Epub Date: 2026-03-13 DOI:10.1007/s10557-026-07852-z
Guofeng Zhu, Haiyang Fang, Congcong Xu, Kai Zhu, Tieqiu Huang, Wei Zhou, Min Huang
{"title":"E3 Ubiquitin Ligase UBR5 Aggravates Cardiac Hypertrophy Via Inhibiting Nrf2/HO-1 Pathway.","authors":"Guofeng Zhu, Haiyang Fang, Congcong Xu, Kai Zhu, Tieqiu Huang, Wei Zhou, Min Huang","doi":"10.1007/s10557-026-07852-z","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1669-1683"},"PeriodicalIF":3.5000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-026-07852-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
E3泛素连接酶UBR5通过抑制Nrf2/HO-1通路加重心肌肥厚。
目的:病理性心脏肥厚是心力衰竭的主要驱动因素,治疗选择有限。本研究旨在发现病理性心脏重构的新分子调控因子和治疗靶点。方法:在tac诱导的肥厚小鼠心脏和angii处理的新生大鼠心肌细胞(NRCMs)中,通过qRT-PCR和Western blot方法定量检测UBR5的表达。产生心脏特异性Ubr5基因敲除小鼠和Ubr5过表达的nrcm,以评估肥厚表型(心脏重量/胫骨长度比、超声心动图、胎儿基因表达)。机制研究采用免疫共沉淀法证实UBR5-Nrf2结合,随后采用体外泛素化实验证实k48关联的Nrf2多泛素化。结果:UBR5在肥厚性心脏(TAC小鼠)和Ang ii刺激的nrcm中显著上调。心脏特异性Ubr5 KO可显著减轻tac诱导的肥厚、心功能障碍和胎儿基因再激活。相反,UBR5过表达加重了Ang ii诱导的肥厚。在机制上,UBR5直接结合Nrf2,促进其k48连锁的多泛素化和蛋白酶体降解,从而抑制血红素加氧酶-1 (HO-1)的表达。救援实验证实,HO-1下调消除了Ubr5 KO的保护作用,而Nrf2消融消除了Ubr5介导的促肥厚作用。结论:UBR5通过泛素介导的Nrf2失稳和Nrf2/HO-1细胞保护轴的抑制,驱动病理性心肌肥大。靶向UBR5是治疗病理性心脏肥厚和心力衰竭的一种有前景的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy 医学-心血管系统
CiteScore
8.30
自引率
0.00%
发文量
110
审稿时长
4.5 months
期刊介绍: Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书